Clinical Trials
55 trialsPED-DNX2401
Clinica Universidad de Navarra, Universidad de Navarra
ARISTOCRAT
University of Birmingham
MEMMAT
Medical University of Vienna
Phenix
Centre Hospitalier Universitaire Vaudois
Nivolumab for Recurrent or Progressive IDH Mutant Gliomas
Columbia University
OLAGLI
Hospices Civils de Lyon
Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields
Memorial Sloan Kettering Cancer Center
Intraarterial Carboplatin + Caelyx vs Intraarterial Carboplatin + Etoposide Phosphate for Progressing Glioblastoma
Université de Sherbrooke
Lerapolturev in Recurrent Malignant Glioma
Istari Oncology, Inc.
NALIRIBVRG
The Central Hospital of Lishui City
Study of Recombinant Human Endostatin Combined with Temozolomide and Irinotecan in Recurrent Gliomas
Beijing Sanbo Brain Hospital
18F-Fluciclovine PET and Multiparametric MR Imaging
Loma Linda University
A Trial of One-week on/One-week Off Temozolomide Versus Continuous Dose-Intense Temozolomide in Patients With Glioblastoma Multiforme at First Relapse
Beijing Sanbo Brain Hospital
TaRRGET
Prof. Franciszek Lukaszczyk Memorial Oncology Center
CILI
National Cancer Institute, Naples
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
NYU Langone Health
Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.
Grupo Español de Investigación en Neurooncología
Pembrolizumab +/- Bevacizumab for Recurrent GBM
Dana-Farber Cancer Institute
ANG1005 in Patients With Recurrent High-Grade Glioma
Angiochem Inc
ReACT
Celldex Therapeutics
Vinorelbine for Children With Progressive or Recurrent Low-grade Gliomas
Children's National Research Institute
AxiGII
Universitair Ziekenhuis Brussel
A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors
University of California, San Francisco
Antineoplaston Therapy in Treating Patients With Low-Grade Astrocytoma
Burzynski Research Institute
Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Oligodendroglioma
Burzynski Research Institute
CaBaMet
AIO-Studien-gGmbH
Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)
M.D. Anderson Cancer Center
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
Masonic Cancer Center, University of Minnesota
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Children's Oncology Group
A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB)
Novartis
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant
Fred Hutchinson Cancer Center
Randomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured Compared to Avastin/Irinotecan
CytoVac A/S
AMG 102 and Avastin for Recurrent Malignant Glioma
Duke University
Memantine for Recurrent Glioblastoma
University of Rochester
Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory High-Risk NBL.
Nationwide Children's Hospital
HGG-CilMetro
Martin-Luther-Universität Halle-Wittenberg
BIBF 1120 for Recurrent High-Grade Gliomas
Dana-Farber Cancer Institute
Bevacizumab for Recurrent Malignant Glioma
National Institutes of Health Clinical Center (CC)
Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment
University of South Florida
Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases
National Cancer Institute (NCI)
Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation
National Cancer Institute (NCI)
Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy
National Cancer Institute (NCI)
CLBH589C
Duke University
VEG102857
GlaxoSmithKline
Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer
National Cancer Institute (NCI)
Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment
National Cancer Institute (NCI)
Procarbazine and Lomustine in Recurrent Glioblastoma
Incheon St.Mary's Hospital
Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation
Fred Hutchinson Cancer Center
Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme
Myrexis Inc.
Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy
Rigshospitalet, Denmark